A Randomized, Double-Blind, Placebo-Controlled Phase II-III Multi-Centre Study to Evaluate the Effect of Adjuvant Pazopanib (GW786034) Versus Placebo on Post-Surgical Disease-Free Survival in Patients With Stage I Non Small Cell Lung Cancer and Tumor Size Equal or Inferior to 7 cm

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase II-III Multi-Centre Study to Evaluate the Effect of Adjuvant Pazopanib (GW786034) Versus Placebo on Post-Surgical Disease-Free Survival in Patients With Stage I Non Small Cell Lung Cancer and Tumor Size Equal or Inferior to 7 cm

Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 23 Feb 2017 According to results published in the Annals of Oncology, a protocol has amended to reduce dose of the pazopanib from 800 mg/day to 400 mg/day due to insufficient compliance.
    • 23 Feb 2017 Results of phase II part of this study published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top